Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics (Nasdaq: RPTX) announced that its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on April 20 at 9:30 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available for 30 days following the event.
The Company specializes in precision oncology using a proprietary synthetic lethality approach, with notable products in development, including the ATR inhibitor RP-3500 and the PKMYT1 inhibitor RP-6306.
Repare Therapeutics (RPTX) hosted a virtual Investor Day to discuss progress on RP-6306, a selective oral PKMYT1 inhibitor for tumors with CCNE1 amplification. The Company aims to start a Phase 1 clinical trial in Q2 2021, ahead of schedule. Key highlights include compelling pre-clinical data supporting RP-6306's efficacy as a monotherapy and in combination therapies. Repare's CRISPR-based SNIPRx platform identified PKMYT1 as a significant target for cancers resistant to existing treatments, addressing a rising unmet medical need in oncology.
Repare Therapeutics (Nasdaq: RPTX) will host a virtual Investor Day on April 8, 2021, from 10:30 a.m. to 12:00 p.m. ET. The event will feature discussions on RP-6306, a novel inhibitor targeting CCNE1 amplification, with a Phase 1 clinical trial expected to commence in Q2 2021, a quarter ahead of prior guidance. The trial aims to evaluate safety and establish the recommended Phase 2 dose for patients with recurrent CCNE1 amplified tumors. Repare leverages its SNIPRx platform to develop targeted cancer therapies.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced the establishment of Automatic Securities Disposition Plans (ASDPs) by its Executives, Steve Forte and Maria Koehler. These plans comply with U.S. and Canadian securities regulations, allowing orderly share sales while preventing insider trading. Up to 42,182 shares may be sold under these ASDPs over approximately 14 months. Sales will commence post the filing of Form 10-Q for Q1 2021. The ASDPs include restrictions to mitigate risks associated with material non-public information and allow only one plan per Executive.
Repare Therapeutics (Nasdaq: RPTX) reported its financial results for Q4 and full year 2020, highlighting strong capital raising and clinical progress.
The company secured over $300 million, advancing its Phase 1/2 trial for RP-3500. They activated 10 clinical sites across North America and Europe for the trial. Repare also initiated IND-enabling studies for RP-6306 and expects to launch its trial by Q2 2021, earlier than planned. However, the company reported a net loss of $53.4 million for the year, a significant increase from $27.2 million in 2019.
Repare Therapeutics (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in three virtual investor conferences in March 2021. Key events include the Cowen 41st Annual Healthcare Conference on March 2, focusing on ovarian cancer, and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Additionally, Repare will attend the Morgan Stanley Virtual Healthcare Corporate Access Day on March 16. The H.C. Wainwright presentation will be available for replay on the Company’s website for 30 days, showcasing its innovative cancer therapies and pipeline development.
Repare Therapeutics, Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced CEO Lloyd M. Segal's participation in two virtual investor conferences. The H.C. Wainwright Virtual BioConnect Conference will be from January 11-14, 2021, with a pre-recorded presentation available on January 11 at 6:00 a.m. ET. The 39th Annual J.P. Morgan Healthcare Conference is scheduled for January 14, 2021, at 8:20 a.m. ET, featuring a live webcast. Repare focuses on developing targeted cancer therapies through its SNIPRx® platform, with notable products like RP-3500.
Repare Therapeutics (Nasdaq: RPTX) has announced the implementation of Automatic Securities Disposition Plans (ASDPs) by its executives and other insiders, allowing for the orderly sale of their shares over the next 12 to 24 months. The ASDPs comply with U.S. and Canadian securities laws, ensuring trades occur without access to undisclosed material information. A total of 439,272 common shares may be sold under these plans, with established trading parameters exceeding current market prices.
Repare Therapeutics (Nasdaq: RPTX) has announced its addition to the NASDAQ Biotechnology Index, effective December 21, 2020. This is a significant milestone for the company, renowned for its innovative synthetic lethality approach in oncology. The NASDAQ Biotechnology Index tracks the performance of biotechnology and pharmaceutical companies listed on NASDAQ, ensuring those meet specific market value and trading volume criteria. Repare's SNIPRx® platform is pivotal in developing targeted cancer therapies, including its lead candidate RP-3500, an ATR inhibitor.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that its CEO, Lloyd M. Segal, will engage in a fireside chat during the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The discussion will be available for replay on the company’s website in the Investor section for 90 days. Repare specializes in precision oncology using its SNIPRx® platform to develop innovative cancer therapies focusing on genomic instability. Key products include the ATR inhibitor RP-3500 and CCNE1-SL inhibitor programs.
